Drug Delivery Business3d
Trinity Biotech to undergo strategic realignment, focus on CGM development
Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.
Hosted on MSN5mon
FDA Clears the First Implantable Continuous Glucose Monitor That Can Last a Year
The Eversense 365 implant features a small sensor ... “The approval of Eversense 365 represents a significant leap in CGM innovation. Extending sensor longevity to a full year, coupled with ...